RedHill Biopharma

Company snapshot

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases. RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S. RedHill’s pipeline includes several drug candidates in advanced clin

• 14 active pipeline program(s) linked via ClinicalTrials.gov.
• 40 US patent(s) indexed to this assignee profile.
• 14 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for RedHill Biopharma. Not investment advice.

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 40

• Peer + 0 momentum

  Vir Biotechnology

  TA overlap score 26.8

• Peer + 0 momentum

  Arcturus Therapeutics

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for RedHill Biopharma.

1. Jun 8, 2026 Clinical update

   RHB-104-04 — Phase 3

2. Jun 8, 2026 Clinical update

   Rifamycin SV-MMX — Phase 2

3. Jun 8, 2026 Clinical update

   Part A: Upamostat 200 mg — Phase 3

4. Jun 8, 2026 Clinical update

   Opaganib — Phase 3

5. Jun 5, 2026 Clinical update

   Upamostat — Phase 2

View all clinical trial activity →

• What is RedHill Biopharma?

  RedHill Biopharma is a biotech organization headquartered in Raleigh, USA. It trades on NYSE under ticker RDHL. Primary therapeutic focus areas include Cholangiocarcinoma, Irritable Bowel Syndrome With Diarrhea, Coronavirus Infections, COVID-19, Covid19. NovaPharmaNews links 14 c

• Is RedHill Biopharma publicly traded?

  Yes. RedHill Biopharma is listed with ticker RDHL on NYSE per SEC EDGAR records linked on this profile.

• What drugs does RedHill Biopharma develop or market?

  We link 10 drug profile(s) where RedHill Biopharma is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/redhill-biopharma#company-drugs.

• What are the latest developments for RedHill Biopharma?

  In the last 12 months our linked public records show 14 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does RedHill Biopharma focus on?

  RedHill Biopharma focuses on Cholangiocarcinoma, Irritable Bowel Syndrome With Diarrhea, Coronavirus Infections based on our analysis of their pipeline programs and drug development activities.